Pharmaceutical News RSS Feed - Pharmaceutical News

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
New analysis looks at costly impact of new Hepatitis C treatments in California

New analysis looks at costly impact of new Hepatitis C treatments in California

A new analysis and infographic released today estimate California's exposure to high-priced Hepatitis C medications could range from hundreds of millions of dollars, even if only 5 percent of Californians infected with Hepatitis C receive treatment through state programs. [More]
Telesta submits Biologics License Application for MCNA to FDA

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. [More]
STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States. [More]
New paper evaluates effect of topical benzoyl peroxide on Propionibacterium acnes during shoulder surgery

New paper evaluates effect of topical benzoyl peroxide on Propionibacterium acnes during shoulder surgery

A new paper to be published in The Journal of Shoulder and Elbow Surgery evaluates the effect that topical benzoyl peroxide (BPO), with chlorhexidine skin preparation, has on the presence of Propionibacterium acnes cultured at the time of shoulder surgery. The authors hypothesized that adding topical BPO, the active ingredient in Clearasil, to the pre-operative skin preparation would reduce the number of positive P. acnes cultures identified during surgery. [More]

Enhancements to Reaxys Medicinal Chemistry address workflow, data challenges of early drug discovery

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced enhancements to Reaxys Medicinal Chemistry that address the critical workflow and data challenges of early drug discovery. [More]
Marken to deliver clinical trial drugs in Korea during MERS outbreak

Marken to deliver clinical trial drugs in Korea during MERS outbreak

Marken, the leading clinical trial logistics organization providing solutions and services to the life sciences industry, has been granted permission by the government to deliver the first direct to patient shipment of clinical drug product in Korea. [More]
Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
New study examines how reasons for illicit marijuana use relate to use of other drugs

New study examines how reasons for illicit marijuana use relate to use of other drugs

Marijuana is the most prevalent drug in the U.S. Approximately 70% of the 2.8 million individuals who initiated use of illicit drugs in 2013 reported that marijuana was their first drug. [More]

Improved medicine packaging designs increase caregivers' willingness to provide ORS to children

The usage of key medicines in developing countries could be significantly increased through improved packaging appearance, a new study by the Clinton Health Access Initiative, Inc. (CHAI) and the University of Warwick finds. [More]
Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival. [More]
Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

Government of the Republic of Equatorial Guinea to sponsor development of Sanaria PfSPZ Vaccine for malaria

The Government of the Republic of Equatorial Guinea announced an agreement with industry partners, Marathon Oil Corporation, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 until 2018. [More]
Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it. [More]
SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine. [More]
Two antibodies show early promise in preventing and treating MERS

Two antibodies show early promise in preventing and treating MERS

As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia. [More]
Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

Amphetamine-based drug Evekeo effective in treating ADHD symptoms in children

The amphetamine-based drug Evekeo, given once or twice daily to children 6-12 years of age, is effective in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, according to the results of a new study published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. [More]
Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020. [More]
Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study. [More]

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
Advertisement
Advertisement